Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - paricalcitol - injection - 5 mcg/ml - paricalcitol 5 mcg/ml

United States - English - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - paricalcitol - solution for injection - 5microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - paricalcitol - solution for injection - 5microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - paricalcitol - solution for injection - 5microgram/1ml

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules - paricalcitol 1 mcg - paricalcitol - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Canada - English - Health Canada

abbvie corporation - paricalcitol - solution - 5mcg - paricalcitol 5mcg - vitamin d

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.